CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab
Authors:
- 12 December 2006
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 56 (7) , 1107-1117
Abstract
Tumor-targeted delivery of a potent cytotoxic agent, calicheamicin, using its immunoconjugates is a clinically validated therapeutic strategy. Rituximab is a human CD20-specific chimeric antibody extensively used in B-NHL therapy. We investigated whether conjugation to calicheamicin can improve the anti-tumor activity of rituximab against human B-cell lymphoma (BCL) xenografts in preclinical models. BCL cells were cultured with rituximab or its calicheamicin conjugates and their in vitro growth was monitored. BCL cells were injected s.c. to establish localized xenografts in nude mice or i.v. to establish disseminated BCL in severe combined immunodeficient (scid) mice. I.p. treatment with rituximab or its calicheamicin conjugates was initiated and its effect on s.c. BCL growth or survival of mice with disseminated BCL was monitored. Conjugation of calicheamicin to rituximab vastly enhanced its growth inhibitory activity against BCL in vitro. Conjugation to calicheamicin had no deleterious effect on the effector functional activity of rituximab. Calicheamicin conjugated to rituximab with an acid-labile linker exhibited greater anti-tumor activity against s.c. BCL xenografts and improved survival of mice with disseminated BCL over that of unconjugated rituximab. Anti-tumor activities of rituximab conjugated to calicheamicin via an acid-stable linker were similar to that of unconjugated rituximab. Superior anti-tumor efficacy exhibited by a calicheamicin immunoconjugate of rituximab with an acid-labile linker over that of rituximab demonstrates the therapeutic potential of CD20-specific antibody-targeted chemotherapy strategy in the treatment of B-NHL.Keywords
This publication has 31 references indexed in Scilit:
- Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin ConjugatesClinical Cancer Research, 2004
- Tumour-targeted chemotherapy with immunoconjugates of calicheamicinExpert Opinion on Biological Therapy, 2004
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyJournal of Experimental Medicine, 2004
- Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsBlood, 2004
- Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesBlood, 2004
- Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood, 2003
- Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell LinesCellular Immunology, 2000
- Therapy of human B‐cell lymphoma bearing scid mice is more effective with anti‐CD19‐and anti‐CD38‐saporin immunotoxins used in combination than with either immunotoxin used aloneInternational Journal of Cancer, 1995
- Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization.Journal of Cell Biology, 1992
- Calicheamicin γ 1 I : an Antitumor Antibiotic That Cleaves Double-Stranded DNA Site SpecificallyScience, 1988